<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometrial carcinoma: Serous and clear cell histologies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometrial carcinoma: Serous and clear cell histologies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometrial carcinoma: Serous and clear cell histologies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter E Schwartz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endometrioid adenocarcinoma is the most common type of endometrial carcinoma. Nonendometrioid subtypes, including serous and clear cell carcinomas, are less common than endometrioid tumors, but account for almost half of endometrial cancer deaths.</p><p>Information specific to serous and clear cell endometrial carcinomas is reviewed here. Related content is discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Overview of endometrial carcinoma (see  <a class="medical medical_review" href="/z/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathology and pathogenesis (see  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology and risk factors (see  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features, diagnosis, and screening for high-risk patients (see  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Staging and surgical treatment (see  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant therapy (see  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>)</p><p></p><p class="headingAnchor" id="H3674282050"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system classifies serous and clear cell endometrial cancers as "aggressive" tumors, along with grade 3 endometrioid tumors and mixed, undifferentiated, mesonephric-like, and gastrointestinal-type mucinous carcinomas [<a href="#rid1">1</a>]. By contrast, endometrioid tumors that are grade 1 or 2 and nongastrointestinal-type mucinous tumors represent less aggressive histologies and are termed "nonaggressive" in the 2023 FIGO staging system. These two categories differ in incidence, responsiveness to hormones, and clinical behavior and impact surgical and postoperative treatment [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Histopathology'</a> and  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'FIGO categorization'</a>.)</p><p>Other classification systems (eg, type I and type II; World Health Organization [WHO] categorization of tumors of the uterine corpus) are described separately. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Traditional classification system'</a> and  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'WHO categorization'</a>.)</p><p>This topic will utilize the 2023 FIGO staging system except when describing studies that used older staging systems. </p><p class="headingAnchor" id="H4548929"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H1962297"><span class="h2">Precursor lesions</span><span class="headingEndMark"> — </span>Uterine serous carcinomas are thought to develop from endometrial intraepithelial carcinomas (EIC; also referred to as hyperplasia with atypia), a lesion related to malignant transformation of the endometrial surface epithelium (such as a benign endometrial polyp) against a background of endometrial atrophy [<a href="#rid3">3,4</a>]. They may also be associated with extrauterine serous carcinoma, with both sites having identical clones of <em>p53 </em>mutations [<a href="#rid5">5</a>]. This finding has led some to suggest that EIC represents an early form of uterine serous carcinoma rather than its true precursor [<a href="#rid6">6</a>]. Endometrial glandular dysplasia, which histologically bridges benign endometrium and EIC, may be the putative precursor lesion to uterine serous carcinoma [<a href="#rid7">7</a>].</p><p>A putative precursor lesion for endometrial clear cell carcinoma characterized by nuclear atypia has also been described [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H1962449"><span class="h2">Molecular pathogenesis</span><span class="headingEndMark"> — </span>Uterine serous and clear cell tumors also appear to have a different pattern of molecular alterations that underlie pathogenesis and/or progression [<a href="#rid9">9</a>]. While alterations in the tumor suppressor gene <em>PTEN</em>, microsatellite instability (MSI), and K-ras alterations have been associated with the early development of endometrioid tumors, these alterations are uncommon in uterine serous and clear cell cancers. Rather, <em>p53</em> mutations appear to be important in the early pathogenesis of uterine serous carcinomas. Moreover, human epidermal growth factor receptor 2 (HER2) overexpression/amplification has also been associated with serous and clear cell carcinomas. Other somatic mutations that have been described in patients with uterine serous carcinomas include <em>PIK3CA</em>, <em>FBXW7</em>, <em>PPP2R1A</em>, and amplification of <em>CCNE1</em> [<a href="#rid10">10</a>]. These issues are discussed in detail separately. (See <a class="local">'Prognosis'</a> below and  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Integration of molecular subtypes'</a>.)</p><p>There are conflicting data regarding whether uterine serous carcinomas are one of the spectrums of cancers in patients with <em>BRCA1</em> or <em>2</em> gene mutations. In a multicentre, prospective cohort study including 828 <em>BRCA</em> mutation carriers (160 of whom used <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>), five incident cases of endometrioid-type uterine cancer were identified compared with 2.04 expected (standardized incidence ratio 2.45; 95% CI 0.80-5.72) during a median follow-up of nine years; there were no uterine serous cancers identified [<a href="#rid11">11</a>]. By contrast, uterine serous carcinomas appear to be more common in patients with <em>BRCA</em> mutations of Jewish ancestry, particularly those of Ashkenazi descent. In one report including 27 patients with uterine serous carcinomas, 74 percent were of Jewish Ashkenazi origin, and of these patients, four (20 percent) had <em>BRCA1</em> germline mutations [<a href="#rid12">12</a>]. In another retrospective study of 22 patients on Jewish ancestry with uterine serous carcinomas, <em>BRCA</em> germline mutations were identified in six (27 percent) patients [<a href="#rid13">13</a>]. In a review from Israeli medical centers, 14 of 60 patients (23 percent) with uterine serous carcinomas had an inherited <em>BRCA</em> gene mutation [<a href="#rid14">14</a>]. Patients with <em>BRCA</em> gene mutations tended to present with more advanced disease, but the disease-specific survival was similar to that of noncarriers.</p><p class="headingAnchor" id="H4548904"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Serous and clear cell carcinomas, along with other nonendometrioid histologies, account for 10 to 20 percent of endometrial carcinomas [<a href="#rid2">2,15</a>]. Since they are less common than endometrioid carcinomas, there are fewer epidemiologic data about them. </p><p>Risk factors for serous and clear cell endometrial carcinomas, in addition to other "aggressive" tumors (see <a class="local">'Classification'</a> above), have also traditionally been thought to differ from endometrioid tumors in several ways; some of these are well established, but others are controversial [<a href="#rid16">16,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The average age at diagnosis is older in most studies [<a href="#rid2">2,18</a>]. However, in a prospective study including over 9227 females from Norway with a cancer of the uterine corpus and followed for an average of 25 years, those with type II (992 patients) compared with type I carcinomas had a similar age at diagnosis (mean age, 65 years in both groups) [<a href="#rid19">19</a>]. By comparison, the average age at diagnosis of all uterine cancers in the United States is 62 years old [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients tend to have a lower body mass index (BMI) than those with endometrioid endometrial carcinoma [<a href="#rid17">17</a>]. However, there is evidence that obesity is a risk factor for all endometrial carcinomas [<a href="#rid19">19,21</a>]. As an example, in the cohort study including patients from Norway cited above, obesity was associated with an increased risk of either type of tumor, but the risk was more pronounced for type I [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are more likely to be parous than nulliparous [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Black patients are more likely than White patients to have aggressive histologies [<a href="#rid16">16,24,25</a>], which may contribute to the poorer overall prognosis for Black patients compared with White patients with endometrial carcinoma [<a href="#rid26">26,27</a>]. Race-based biases, socioeconomic factors, and disparities in access to care likely contribute to this disparity rather than race itself. This is also discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Other factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A personal history of breast cancer appears to be associated with a risk of developing uterine clear cell carcinoma, but this relationship is uncertain [<a href="#rid16">16,28,29</a>]. In a case-control study of patients with endometrial carcinoma, patients with serous histology were more likely than those with endometrioid histology to have a personal history of breast cancer (19 versus 3 percent) [<a href="#rid29">29</a>]. This risk does not appear to be dependent upon use of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>. In addition, there have been some reports that the <em>BRCA1</em> mutation carriers are at an increased risk of uterine serous carcinoma [<a href="#rid17">17</a>]. (See <a class="local">'Molecular pathogenesis'</a> above.)</p><p></p><p>Unlike other clear cell carcinomas (eg, of the ovary), endometriosis does <strong>not</strong> appear to be a risk factor for the development of clear cell carcinoma of the uterus [<a href="#rid30">30</a>].</p><p>General information about the epidemiology of endometrial carcinomas is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H2028614"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>As with endometrioid tumors, abnormal uterine bleeding is the most common clinical presentation for patients with serous and clear cell tumors. Likewise, some patients present with endometrial cells on cervical cytology. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H2028622"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H3677589313"><span class="h2">Tissue sampling</span><span class="headingEndMark"> — </span>As with other types of endometrial carcinoma, serous and clear cell endometrial cancer is a histologic diagnosis made based on histologic evaluation of endometrial sampling, curettage, or a hysterectomy specimen. (See  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Diagnosis'</a>.)</p><p>An office endometrial biopsy is a sensitive test for aggressive endometrial carcinomas. However, the correct histology may not be identified in all cases. As an example, in one study including 67 patients with a final postoperative diagnosis of uterine serous carcinoma, 25 percent were initially reported as endometrioid histology based on endometrial biopsy [<a href="#rid31">31</a>]. There were also a few cases (2 of 234 patients) of a false-positive diagnosis of uterine serous carcinoma. These findings may reflect that uterine serous carcinomas can be of mixed histology, as discussed below. (See <a class="local">'Histologic diagnosis'</a> below.) </p><p>Dilation and curettage, with or without hysteroscopy, may be performed in those who cannot tolerate an office biopsy, in whom the office procedure is unsuccessful, or those at very high risk of endometrial cancer. </p><p class="headingAnchor" id="H394937717"><span class="h2">Histologic diagnosis</span><span class="headingEndMark"> — </span>The histology of serous and clear cell carcinomas is presented here; the histology of endometrioid tumors is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Endometrioid carcinoma'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serous carcinomas</strong> – Uterine serous carcinomas have a complex papillary architecture that resembles serous carcinoma of the ovary  (<a class="graphic graphic_picture graphicRef108725" href="/z/d/graphic/108725.html" rel="external">picture 1</a>); psammoma bodies are present in 60 percent of cases [<a href="#rid32">32,33</a>]. Marked nuclear atypia is always present, and all uterine serous carcinomas are considered high grade.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clear cell carcinomas</strong> – Clear cell cancers are characterized by tubulocystic, papillary, or solid patterns  (<a class="graphic graphic_picture graphicRef108726" href="/z/d/graphic/108726.html" rel="external">picture 2</a>); psammoma bodies are present in up to 32 percent of cases, most often in the papillary variant [<a href="#rid34">34,35</a>]. The cells may be clear because of the presence of glycogen. Myometrial invasion occurs in approximately 80 percent of cases. While clear cell cancers appear more similar to clear cell cancers arising in other organs (eg, the kidney) than to other uterine cancers, including those of the serous variety [<a href="#rid36">36</a>], they are nevertheless treated similar to serous cancers. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed-histology tumors</strong> – Uterine serous and clear cell carcinomas may be a component of mixed-histology tumors that have endometrioid or sarcomatous elements. If 10 percent or more of the tumor has a serous component, it is classified as uterine serous carcinoma; cases in which the serous component consists of more than 10 percent but less than 90 percent of the cancer are classified as mixed serous cancers. For clear cell carcinomas, some pathologists require ≥50 percent clear cell features to classify a tumor as a clear cell carcinoma [<a href="#rid37">37</a>], while others use the benchmark of at least 25 percent clear cell component [<a href="#rid38">38,39</a>]. </p><p></p><p class="headingAnchor" id="H3459049278"><span class="h2">Role of tumor markers</span><span class="headingEndMark"> — </span>If a serous or clear cell uterine cancer is suspected or diagnosed on an endometrial specimen, a serum cancer antigen (CA) 125 level should be ordered. </p><p>Retrospective studies have consistently reported that elevated levels of CA 125 are associated with uterine serous and clear cell cancers, as well as advanced stage, poorly differentiated endometrioid adenocarcinomas [<a href="#rid16">16,40-44</a>]. Elevations of CA 125 are also associated with positive pelvic node involvement, positive peritoneal washings, and the presence of lymphovascular invasion [<a href="#rid45">45</a>]. Thus, knowing a patient may have an advanced-stage uterine cancer may influence the surgery to be performed and determine the need for a gynecologic oncologist to perform that surgery. (See <a class="local">'Surgical staging'</a> below.)</p><p>However, the prognostic effect of an elevated CA 125 on progression-free survival remains controversial and elevated serum CA 125 levels may not be associated with disease recurrence [<a href="#rid42">42,45</a>]. </p><p class="headingAnchor" id="H534857721"><span class="h2">Limited role of transvaginal ultrasound</span><span class="headingEndMark"> — </span>While transvaginal ultrasound (TVUS) may initially be used to evaluate the endometrium in some patients, endometrial thickness does <strong>not</strong> reliably exclude serous and clear cell cancers [<a href="#rid46">46</a>]. TVUS, however, may be used to assess for other pelvic pathology (eg, adnexal mass).</p><p>Use of TVUS to evaluate the endometrium is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Transvaginal ultrasound'</a>.)</p><p class="headingAnchor" id="H3381659526"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H6"><span class="h2">Surgical staging</span><span class="headingEndMark"> — </span>As with other endometrial cancers, serous and clear cell endometrial carcinomas are surgically staged  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 2</a>). Staging of endometrial cancer is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p>Unlike with some endometrioid tumors, omentectomy and pelvic washings are often performed when staging uterine serous or clear cell cancers.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omentectomy</strong> – The omentum appears to be the most common intra-abdominal site for metastatic disease in such patients. In a cohort study of 40 patients with surgically staged, histologically pure, serous cancers with invasion limited to the endometrium or without stromal invasion, extrauterine intra-abdominal cancers were found in 18 (45 percent) patients [<a href="#rid47">47</a>]. Of these 18 patients, 78 percent had disease of the omentum: 10 patients had gross evidence of tumor deposits (ranging from 0.5 cm to bulky lesions), and an additional four patients had microscopic disease despite a normally appearing omentum. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pelvic washings</strong> – We perform pelvic washings in patients with serous and clear cell histologies as the presence of cancer cells in the peritoneal cavity is a poor prognostic factor for such patients. However, this practice is controversial, and pelvic washings are not part of the International Federation of Gynecology and Obstetrics (FIGO) endometrial cancer staging system, which is largely based on data from studies of endometrioid endometrial cancers [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment", section on 'Staging system'</a>.)</p><p></p><p class="bulletIndent1">While malignant cells in peritoneal washings are found in approximately 5 percent of patients with early stage endometrioid endometrial cancers, higher rates have been reported in those with nonendometrioid endometrial cancers [<a href="#rid48">48,49</a>]. In a retrospective study of data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database, peritoneal cytology was positive in 214 of 1508 (14 percent) patients with uterine serous cancers confined to the endometrium and in 30 of 278 (10.8 percent) of patient with uterine clear cell cancers confined to the endometrium [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent1">Malignant cells in peritoneal washings have been associated with decreased survival. In the retrospective study of SEER data discussed above, the five-year overall survival was lower for those with positive compared with negative cytology (uterine serous: 60 versus 77 percent; clear cell: 56 versus 80 percent) [<a href="#rid48">48</a>]. However, this study had limitations including being retrospective, lacking a central pathology review, possible lead-time bias and a lack of knowledge as to why some patients received adjuvant therapy and others did not. Other studies containing small numbers of patients have reported similar results; adjuvant therapy was administered to most patients in these studies [<a href="#rid50">50-52</a>]. In one retrospective study of 68 patients with stage I and II uterine serous cancer for whom their institutional policy was to not administer adjuvant therapy, those with positive compared with negative pelvic cytology had worse five-year disease-free (hazard ratio [HR] 4.2, 95% CI 1.6-11.5) and overall (HR 4.96, 95% CI 1.3-18.3) survival [<a href="#rid53">53</a>].</p><p></p><p>Optimal cytoreduction is an important component of surgical treatment [<a href="#rid54">54-61</a>]. The strongest predictor of overall survival is the amount of residual disease following surgery [<a href="#rid54">54-60</a>]. In a retrospective review of 70 patients with stage IIIC or IV uterine serous carcinoma, those with optimal cytoreduction with no visible residual disease compared with optimal cytoreduction with macroscopic residual disease and suboptimal cytoreduction had improved rates of survival (median survival: 51 versus 14 and 12 months, respectively) [<a href="#rid55">55</a>]. Outcomes in the group with residual disease were not substantially improved by the use of postoperative chemotherapy. </p><p class="headingAnchor" id="H2028630"><span class="h2">Adjuvant therapy</span><span class="headingEndMark"> — </span>Serous and clear cell endometrial carcinomas are considered high-risk disease and patients with such cancers should be offered adjuvant chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p class="headingAnchor" id="H27281460"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H3099355123"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Serous and clear cell endometrial carcinomas have been associated with a poorer outcome than endometrioid tumors in most, but not all studies [<a href="#rid39">39,62-70</a>]. They also have a higher propensity for intraperitoneal and extra-abdominal spread, as well as lymphovascular invasion [<a href="#rid62">62,63,71-75</a>]. At the time of presentation, approximately 50 to 70 percent of patients with uterine serous carcinomas will have disease spread outside of the uterus [<a href="#rid54">54,62,75,76</a>]. Even having as little as 10 percent of the tumor composed of uterine serous carcinoma places the patient at increased risk of metastasis [<a href="#rid77">77</a>].</p><p>In a study of 4180 patients with high-risk endometrial carcinoma subtypes reported to the Surveillance, Epidemiology and End Results (SEER) United States National Cancer Database between 1988 and 2001, uterine serous and clear cell carcinomas accounted for 10 and 3 percent of all endometrial carcinomas, but were responsible for 39 and 8 percent of all deaths, respectively [<a href="#rid67">67</a>]. The five-year disease-specific survival rates for serous and clear cell were 55 and 68 percent, respectively. These statistics were confirmed in 2000 to 2015 SEER data, which were corrected for hysterectomy and estimated separately by race, ethnicity, and region in the United States, and histologic subtype  (<a class="graphic graphic_table graphicRef139473" href="/z/d/graphic/139473.html" rel="external">table 3</a>) [<a href="#rid69">69</a>]. The overall combined five-year survival rate for serous and clear cell cancers was 57.5 percent; the corresponding value for endometrioid cancers was 91.8 percent. Even among patients with surgically staged, node-negative, stage I uterine serous carcinoma, the five-year overall survival rate is approximately 70 percent [<a href="#rid66">66</a>]. Patients with clear cell carcinoma have a similar prognosis; five-year overall survival is estimated at 62.5 percent [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1773668206"><span class="h2">Prognostic factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pure serous histologies</strong> – Earlier studies suggested little difference in survival when patients with pure serous cancers were compared with those with mixed serous cancers [<a href="#rid62">62,78-80</a>]. However, in a multi-institutional series comparing 58 patients with mixed uterine serous carcinomas with 50 patients with pure uterine papillary serous carcinomas, the two most important prognostic factors for progression-free and overall survival were stage and pure serous histology [<a href="#rid81">81</a>]. Patients with pure compared with mixed uterine serous histology had a 2.9-fold greater risk for recurrence and a 2.6-fold higher risk of death [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1">By contrast, patients with pure clear cell and mixed clear cell cancers with endometrioid components have similar survival as those whose clear cell cancers containing less histologically favorable components [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor grade and depth of invasion </strong>– While the incidence of extrauterine spread in endometrioid cancer correlates with both tumor grade and depth of myometrial invasion, tumor grade and depth of myometrial invasion are <strong>not</strong> predictive of extrauterine spread for uterine serous carcinomas  (<a class="graphic graphic_table graphicRef119743" href="/z/d/graphic/119743.html" rel="external">table 4</a>). In one cohort study including patients with uterine serous carcinoma, patients with no myometrial involvement compared with inner one-half or outer one-half myometrial invasion had lymph node metastases in 36, 50, and 46 percent of cases, respectively [<a href="#rid64">64</a>]. The corresponding rates of intraperitoneal disease for these three groups were 43, 37, and 35 percent, respectively. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular factors</strong> – Prognosis can be further informed by molecular factors, including POLE/ultramutated (POLE<sub>mut</sub>), mismatch repair-deficient tumors (MMRd)/microsatellite instability, and somatic copy-number alterations, including TP53 mutations (p53abn)  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. In general, patients with POLE<sub>mut</sub> tumors appear to have excellent disease-free survival, while patients with p53 mutated (p53<sub>abn</sub>) tumors appear to experience worse outcomes. Patients with tumors expressing POLEmut or MMRd and a secondary p53 abnormality should not be classified as p53abn as they retain the favorable prognosis of POLEmut or MMRd tumors. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Integration of molecular subtypes'</a>.)</p><p></p><p class="bulletIndent1">Overexpression or amplification of HER2 (erbB-2, the epidermal growth factor receptor 2 gene) has also been identified in a number of studies as a poor prognostic sign for serous and clear cell carcinomas [<a href="#rid82">82-87</a>]. In a series of 30 patients undergoing treatment for uterine serous carcinoma (the majority with stage III or IV disease) at a single institution over a seven-year period, amplification of the <em>HER2</em> gene (as detected by fluorescence in situ hybridization [FISH]) was observed in almost half (47 percent) of patients [<a href="#rid82">82</a>]. At four years, disease-specific survival rates for those with FISH-positive and FISH-negative tumors were 17 and 84 percent, respectively. Management of patients with advanced-stage, previously untreated uterine serous tumors with overexpression of HER2 is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/126055.html" rel="external">"Initial treatment of metastatic endometrial cancer", section on 'HER2-overexpressing serous tumors'</a>.)</p><p></p><p class="headingAnchor" id="H119718345"><span class="h1">POSTTREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>Clear cell carcinomas are more likely than either endometrioid cancers or uterine serous carcinomas to recur with distant spread (eg, to the lungs and bones) [<a href="#rid38">38</a>]. The recurrence pattern of serous endometrial cancer is similar to epithelial ovarian cancer.</p><p>Posttreatment surveillance protocols are the same for other types of endometrial carcinomas. This topic is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Post-treatment considerations'</a>.)</p><p class="headingAnchor" id="H4116150238"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Endometrioid adenocarcinoma is the most common type of uterine cancer. Nonendometrioid subtypes, including serous and clear cell carcinomas  (<a class="graphic graphic_picture graphicRef108725" href="/z/d/graphic/108725.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef108726" href="/z/d/graphic/108726.html" rel="external">picture 2</a>), are less common than endometrioid tumors, and are classified by the International Federation of Gynecology and Obstetrics (FIGO) staging system as "aggressive" tumors, along with grade 3 endometrioid tumors, mixed, undifferentiated, mesonephric-like, and gastrointestinal-type mucinous carcinomas. (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient characteristics</strong> – Patients with serous and clear cell endometrial carcinomas have different characteristics than those with endometrioid tumors. They tend to be older at diagnosis, have a lower body mass index (BMI), and parous. A personal history of breast cancer also appears to be a risk factor for uterine serous carcinoma. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial carcinoma is a histologic diagnosis made based on histologic evaluation of endometrial sampling, curettage, or a hysterectomy specimen. (See <a class="local">'Diagnostic evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with suspected or confirmed serous or clear cell uterine cancer, cancer antigen (CA) 125 levels are obtained preoperatively. Elevations of CA 125 are associated with positive pelvic node involvement, positive peritoneal washings, and the presence of lymphovascular invasion; knowing in advance a patient may have an advanced-stage uterine cancer can influence the surgery to be performed and determine the need for a gynecologic oncologist to perform that surgery. (See <a class="local">'Role of tumor markers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical staging</strong> – Serous and clear cell endometrial carcinomas are surgically staged in the same manner as endometrioid tumors  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 2</a>). However, as these tumors are at high risk of nodal and extrauterine metastasis, omentectomy and pelvic washings are also often performed. Optimal cytoreduction is an important component of surgical treatment. (See <a class="local">'Surgical staging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjuvant therapy</strong> – Serous and clear cell endometrial carcinomas are considered high-risk disease and patients with such cancers should be offered adjuvant chemotherapy. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serous and clear cell endometrial carcinomas have been associated with poorer outcomes than endometrioid tumors in some studies  (<a class="graphic graphic_table graphicRef139473" href="/z/d/graphic/139473.html" rel="external">table 3</a>), but the evidence is uncertain. They also have a higher propensity for intraperitoneal and extra-abdominal spread, as well as lymphovascular invasion. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some molecular factors, such as TP53 mutations (p53<sub>abn</sub>) and overexpression or amplification of HER2 (erbB-2, the epidermal growth factor receptor 2 gene) are associated with poor prognosis. By contrast, POLE/ultramutated (POLE<sub>mut</sub>) is associated with an excellent prognosis. (See <a class="local">'Prognostic factors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162:383.</a></li><li><a class="nounderline abstract_t">Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010; 21:1851.</a></li><li><a class="nounderline abstract_t">Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000; 24:726.</a></li><li><a class="nounderline abstract_t">Tolcher MC, Swisher EM, Medeiros F, et al. Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. Int J Gynecol Pathol 2015; 34:57.</a></li><li><a class="nounderline abstract_t">Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 2005; 96:579.</a></li><li><a class="nounderline abstract_t">Zhang L, Kwan SY, Wong KK, et al. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Zheng W, Liang SX, Yu H, et al. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004; 12:207.</a></li><li><a class="nounderline abstract_t">Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol 2006; 30:1519.</a></li><li><a class="nounderline abstract_t">Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444:213.</a></li><li><a class="nounderline abstract_t">Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012; 104:1503.</a></li><li><a class="nounderline abstract_t">Lee YC, Milne RL, Lheureux S, et al. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2017; 84:114.</a></li><li><a class="nounderline abstract_t">Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004; 92:521.</a></li><li><a class="nounderline abstract_t">Biron-Shental T, Drucker L, Altaras M, et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 2006; 32:1097.</a></li><li><a class="nounderline abstract_t">Kadan Y, Raviv O, Segev Y, et al. Impact of BRCA mutations on outcomes among patients with serous endometrial cancer. Int J Gynaecol Obstet 2018; 142:91.</a></li><li><a class="nounderline abstract_t">Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10.</a></li><li><a class="nounderline abstract_t">Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009; 115:142.</a></li><li><a class="nounderline abstract_t">Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011; 54:278.</a></li><li><a class="nounderline abstract_t">Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006; 101:470.</a></li><li><a class="nounderline abstract_t">Bjørge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2007; 120:378.</a></li><li class="breakAll">Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Uterine cancer. http://seer.cancer.gov/statfacts/html/corp.html (Accessed on September 12, 2021).</li><li><a class="nounderline abstract_t">McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008; 17:73.</a></li><li><a class="nounderline abstract_t">Chen Q, Tong M, Guo F, et al. Parity Correlates with the Timing of Developing Endometrial Cancer, But Not Subtype of Endometrial Cancer. J Cancer 2015; 6:1087.</a></li><li><a class="nounderline abstract_t">Datta A, Thomas V, Sebastian A, et al. The clinico pathological features and survival in serous endometrial cancers. Gynecol Oncol Rep 2023; 47:101194.</a></li><li><a class="nounderline abstract_t">Wright JD, Fiorelli J, Schiff PB, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 2009; 115:1276.</a></li><li><a class="nounderline abstract_t">Sanchez-Covarrubias AP, Tabuyo-Martin AD, George S, Schlumbrecht M. African ancestry is associated with aggressive endometrial cancer. Am J Obstet Gynecol 2023; 228:92.</a></li><li><a class="nounderline abstract_t">Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003; 98:176.</a></li><li><a class="nounderline abstract_t">Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 2006; 107:2197.</a></li><li><a class="nounderline abstract_t">Gehrig PA, Bae-Jump VL, Boggess JF, et al. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol 2004; 94:208.</a></li><li><a class="nounderline abstract_t">Liang SX, Pearl M, Liang S, et al. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer 2011; 128:763.</a></li><li><a class="nounderline abstract_t">Saavalainen L, Lassus H, But A, et al. Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study. PLoS One 2021; 16:e0253270.</a></li><li><a class="nounderline abstract_t">Huang GS, Gebb JS, Einstein MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol 2007; 196:243.e1.</a></li><li><a class="nounderline abstract_t">Fader AN, Java J, Tenney M, et al. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol 2016; 143:460.</a></li><li><a class="nounderline abstract_t">Murali R, Davidson B, Fadare O, et al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int J Gynecol Pathol 2019; 38 Suppl 1:S40.</a></li><li><a class="nounderline abstract_t">Fadare O, Zheng W, Crispens MA, et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res 2013; 3:70.</a></li><li><a class="nounderline abstract_t">Gadducci A, Cosio S, Spirito N, Cionini L. Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res 2010; 30:1327.</a></li><li><a class="nounderline abstract_t">Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005; 11:6422.</a></li><li><a class="nounderline abstract_t">Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982; 49:1511.</a></li><li><a class="nounderline abstract_t">Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003; 55:1272.</a></li><li><a class="nounderline abstract_t">Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000; 77:55.</a></li><li><a class="nounderline abstract_t">Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005; 50:585.</a></li><li><a class="nounderline abstract_t">Jhang H, Chuang L, Visintainer P, Ramaswamy G. CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 2003; 188:1195.</a></li><li><a class="nounderline abstract_t">Gupta D, Gunter MJ, Yang K, et al. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer 2011; 21:529.</a></li><li><a class="nounderline abstract_t">Schmidt M, Segev Y, Sadeh R, et al. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma. Int J Gynecol Cancer 2018; 28:1311.</a></li><li><a class="nounderline abstract_t">Roelofsen T, Mingels M, Hendriks JC, et al. Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. Int J Biol Markers 2012; 27:e263.</a></li><li><a class="nounderline abstract_t">Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, et al. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol 2008; 110:293.</a></li><li><a class="nounderline abstract_t">Saccardi C, Spagnol G, Bonaldo G, et al. New Light on Endometrial Thickness as a Risk Factor of Cancer: What Do Clinicians Need to Know? Cancer Manag Res 2022; 14:1331.</a></li><li><a class="nounderline abstract_t">Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005; 18:75.</a></li><li><a class="nounderline abstract_t">Matsuo K, Nusbaum DJ, Matsuzaki S, et al. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecol Oncol 2020; 159:43.</a></li><li><a class="nounderline abstract_t">Matsuo K, Matsuzaki S, Nusbaum DJ, et al. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. Eur J Cancer 2020; 133:33.</a></li><li><a class="nounderline abstract_t">Corey L, Fucinari J, Elshaikh M, et al. Impact of positive cytology in uterine serous carcinoma: A reassessment. Gynecol Oncol Rep 2021; 37:100830.</a></li><li><a class="nounderline abstract_t">Yang J, Yang J, Cao D, et al. Prognostic Value of Peritoneal Cytology in Stage I Serous and Clear Cell Carcinoma of the Endometrium. J Clin Med 2023; 12.</a></li><li><a class="nounderline abstract_t">Cook A, Khalil R, Burmeister C, et al. The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma. Cureus 2021; 13:e13505.</a></li><li><a class="nounderline abstract_t">Tate K, Yoshida H, Ishikawa M, et al. Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. J Gynecol Oncol 2018; 29:e34.</a></li><li><a class="nounderline abstract_t">Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol 2008; 108:293.</a></li><li><a class="nounderline abstract_t">Thomas MB, Mariani A, Cliby WA, et al. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol 2007; 107:190.</a></li><li><a class="nounderline abstract_t">Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81:92.</a></li><li><a class="nounderline abstract_t">Moller KA, Gehrig PA, Van Le L, et al. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 2004; 94:170.</a></li><li><a class="nounderline abstract_t">Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2005; 97:755.</a></li><li><a class="nounderline abstract_t">Marchetti M, Vasile C, Chiarelli S. Endometrial cancer: asymptomatic endometrial findings. Characteristics of postmenopausal endometrial cancer. Eur J Gynaecol Oncol 2005; 26:479.</a></li><li><a class="nounderline abstract_t">Patsavas K, Woessner J, Gielda B, et al. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol 2011; 121:581.</a></li><li><a class="nounderline abstract_t">Rauh-Hain JA, Growdon WB, Schorge JO, et al. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol 2010; 119:299.</a></li><li><a class="nounderline abstract_t">Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91:463.</a></li><li><a class="nounderline abstract_t">Mattes MD, Lee JC, Metzger DJ, et al. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry. J Gynecol Oncol 2015; 26:19.</a></li><li><a class="nounderline abstract_t">Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54:264.</a></li><li><a class="nounderline abstract_t">Black JD, English DP, Roque DM, Santin AD. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond) 2014; 10:45.</a></li><li><a class="nounderline abstract_t">Huh WK, Powell M, Leath CA 3rd, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003; 91:470.</a></li><li><a class="nounderline abstract_t">Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94:642.</a></li><li><a class="nounderline abstract_t">McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 106:16.</a></li><li><a class="nounderline abstract_t">Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. J Clin Oncol 2019; 37:1895.</a></li><li><a class="nounderline abstract_t">Ma X, Cao D, Zhou H, et al. Survival outcomes and the prognostic significance of clinicopathological features in patients with endometrial clear cell carcinoma: a 35-year single-center retrospective study. World J Surg Oncol 2023; 21:106.</a></li><li><a class="nounderline abstract_t">Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6:93.</a></li><li><a class="nounderline abstract_t">Abdulfatah E, Sakr S, Thomas S, et al. Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases. Int J Gynecol Cancer 2017; 27:1714.</a></li><li><a class="nounderline abstract_t">Abeler VM, Vergote IB, Kjørstad KE, Tropé CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996; 78:1740.</a></li><li><a class="nounderline abstract_t">Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995; 14:30.</a></li><li class="breakAll">Goff BA. Surgical treatment of unusual endometrial cancer. In: American Society of Clinical Oncology Educational Book, 40th Annual Meeting, 2004. p.298.</li><li><a class="nounderline abstract_t">Podratz KC, Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol Oncol 2003; 91:461.</a></li><li><a class="nounderline abstract_t">Boruta DM 2nd, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004; 101:2214.</a></li><li><a class="nounderline abstract_t">Ferriss JS, Erickson BK, Shih IM, Fader AN. Uterine serous carcinoma: key advances and novel treatment approaches. Int J Gynecol Cancer 2021; 31:1165.</a></li><li><a class="nounderline abstract_t">Elit L, Kwon J, Bentley J, et al. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol 2004; 92:240.</a></li><li><a class="nounderline abstract_t">Kelly MG, O'malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98:353.</a></li><li><a class="nounderline abstract_t">Roelofsen T, van Ham MA, Wiersma van Tilburg JM, et al. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 2012; 120:1371.</a></li><li><a class="nounderline abstract_t">Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005; 104:1391.</a></li><li><a class="nounderline abstract_t">Peiró G, Mayr D, Hillemanns P, et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 2004; 17:227.</a></li><li><a class="nounderline abstract_t">Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22:3126.</a></li><li><a class="nounderline abstract_t">Banet N, Shahi M, Batista D, et al. HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma. Am J Surg Pathol 2021; 45:708.</a></li><li><a class="nounderline abstract_t">Buza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Arch Pathol Lab Med 2021; 145:687.</a></li><li><a class="nounderline abstract_t">Bell DW, Ellenson LH. Molecular Genetics of Endometrial Carcinoma. Annu Rev Pathol 2019; 14:339.</a></li></ol></div><div id="topicVersionRevision">Topic 3180 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37337978" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : FIGO staging of endometrial cancer: 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628804" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Factors associated with Type I and Type II endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10800992" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25473754" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721397" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32183290" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pathogenesis and Clinical Management of Uterine Serous Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306933" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122507" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Precursors of endometrial clear cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747944" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923510" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802188" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766242" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650962" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29572834" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of BRCA mutations on outcomes among patients with serous endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6822361" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Two pathogenetic types of endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592079" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508697" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413048" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17066451" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Body size in relation to cancer of the uterine corpus in 1 million Norwegian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17066451" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Body size in relation to cancer of the uterine corpus in 1 million Norwegian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187388" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516355" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Parity Correlates with the Timing of Developing Endometrial Cancer, But Not Subtype of Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37234700" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The clinico pathological features and survival in serous endometrial cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204905" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35944605" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : African ancestry is associated with aggressive endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833470" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17001661" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262144" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association between uterine serous carcinoma and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473885" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185779" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346538" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27743738" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30550483" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359866" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530448" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clear cell carcinoma of the endometrium: a biological and clinical enigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166416" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7066860" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654437" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739691" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16220763" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Preoperative serum CA-125 levels in treating endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748476" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : CA 125 levels in the preoperative assessment of advanced-stage uterine cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436701" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29958235" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22865295" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644620" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35401014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : New Light on Endometrial Thickness as a Risk Factor of Cancer: What Do Clinicians Need to Know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389257" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Minimal uterine serous carcinoma: a clinicopathological study of 40 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32690393" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32434109" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34345643" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of positive cytology in uterine serous carcinoma: A reassessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36836143" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic Value of Peritoneal Cytology in Stage I Serous and Clear Cell Carcinoma of the Endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33786214" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29533019" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096208" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825394" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11277657" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262137" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The role of optimal debulking in advanced stage serous carcinoma of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15913742" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16285561" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endometrial cancer: asymptomatic endometrial findings. Characteristics of postmenopausal endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21440290" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Optimal surgical debulking in uterine papillary serous carcinoma affects survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691465" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675663" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25310855" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8088602" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Uterine papillary serous carcinoma: patterns of metastatic spread.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24328598" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675664" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495918" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17574073" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31116674" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36973753" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Survival outcomes and the prognostic significance of clinicopathological features in patients with endometrial clear cell carcinoma: a 35-year single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7102898" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945214" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8859187" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7883423" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7883423" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675662" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Uterine papillary serous carcinomas: the exigency for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452833" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34210768" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Uterine serous carcinoma: key advances and novel treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14751165" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Optimal management for surgically Stage 1 serous cancer of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16005947" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168762" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pure compared with mixed serous endometrial carcinoma: two different entities?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116605" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752523" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284264" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33739786" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32649220" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30332563" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Molecular Genetics of Endometrial Carcinoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
